
Opinion|Videos|October 4, 2024
Treatment Regimen Considerations
Panelists discuss how various patient characteristics, including age, fitness level, cytogenetic risk, and comorbidities, influence their decision to use more intensive quadruplet regimens like D-VRd (daratumumab plus bortezomib, lenalidomide, and dexamethasone) vs standard triplet regimens, such as VRd or KRd (carfilzomib, lenalidomide, and dexamethasone) in transplant-eligible multiple myeloma patients, while also considering administration logistics and supportive care requirements
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What factors around administration logistics and supportive care requirements (eg, premedications, infusion reactions) do you consider when sequencing regimens for transplant-eligible patients?
- (Dr Adams) What patient characteristics would lead you to consider a quadruplet regimen like D-VRd (daratumumab plus bortezomib, lenalidomide, and dexamethasone) compared with a triplet regimen like VRd or KRd (carfilzomib, lenalidomide, and dexamethasone)?
Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves mFlusiva, the First mRNA-Based Influenza Vaccine
2
The Side Door We Could Close: A Pharmacy Perspective on Menopause, Access, and the Leadership Pipeline
3
Tirzepatide Cuts MACE Risk in Diabetes With Heart Disease
4
Study Reveals a Widening Gap Between Buprenorphine Prescribing and Dispensing
5


































































































